Ask the expert. Does antibody induction therapy with daclizumab or basiliximab increase the risk of recurrence of post-transplant focal segmental glomerulosclerosis? (Q77950814)
Jump to navigation
Jump to search
scientific article published on 01 April 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ask the expert. Does antibody induction therapy with daclizumab or basiliximab increase the risk of recurrence of post-transplant focal segmental glomerulosclerosis? |
scientific article published on 01 April 2002 |
Statements
Ask the expert. Does antibody induction therapy with daclizumab or basiliximab increase the risk of recurrence of post-transplant focal segmental glomerulosclerosis? (English)
Marie-France Gagnadoux
1 reference
1 reference